FIROZ CHELAPRAM KANDY

Employment

• Meenakshi Academy of Higher Education and Research Research Scholar
  2022 - Present
• MIMS Academy Assistant Professor
  2022 - 2022
• MES Medical College Assistant Professor
  2020 - 2022
• King Abdulaziz University LECTURER
  2012 - 2018

Education

• University of Calicut MSC MEDICAL LABORATORY TECHNOLOGY
  2006 - 2008

Projects & Funding

Projects & funding information is unavailable.

Publications (29)

• Investigating the Anti-glioblastoma Potential of Alkaloids from the Solanaceae Family: A Multi-Targeted Approach Using Network Pharmacology and Molecular Modeling Approaches
  Journal of Computational Biophysics and Chemistry 2026 DOI: 10.1142/S2737416525500425
  +Save
• A literature perspective on the pharmacological applications of yohimbine
  Annals of Medicine 2022 DOI: 10.1080/07853890.2022.2131330
  +Save
• Sugiol Suppresses the Proliferation of Human U87 Glioma Cells via Induction of Apoptosis and Cell Cycle Arrest
  Evidence-based Complementary and Alternative Medicine 2022 DOI: 10.1155/2022/7658899
  +Save
• Chemical profile and therapeutic potentials of Xylocarpus moluccensis (Lam.) M. roem.: A literature-based review.
  Journal of ethnopharmacology 2020 DOI: 10.1016/j.jep.2020.112958
  +Save
• An Insight on the Pathogenesis and Treatment of Systemic Lupus Erythematosus
  Endocrine, Metabolic & Immune Disorders-Drug Targets 2018 DOI: 10.2174/1871530318666171207145003
  +Save
• An overview on the current status of cancer nanomedicines
  Current Medical Research and Opinion 2018 DOI: 10.1080/03007995.2017.1421528
  +Save
• Effect of Diterpenes on Hepatic System
  Current Pharmaceutical Design 2018 DOI: 10.2174/1381612824666181001152247
  +Save
• The Use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
  Anti-Cancer Agents in Medicinal Chemistry 2018 DOI: 10.2174/1871520616666160520112839
  +Save
• Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
  Current Drug Metabolism 2017 DOI: 10.2174/1389200217666160810155055
  +Save
• Reduction in CD16/CD56 and CD16/CD3/CD56 Natural Killer Cells in Coronary Artery Disease
  Immunological Investigations 2017 DOI: 10.1080/08820139.2017.1306866
  +Save